Claim 55% Off TipRanks
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Discover top-performing stock ideas and upgrade to a portfolio of market leaders with Smart Investor Picks
BerGenBio ASA ( (BRRGF) ) has issued an update.
BerGenBio ASA has announced a fully underwritten rights issue to raise NOK 130 million, following a merger with BerGenBio Norge AS and Oncoinvent ASA. This move is expected to strengthen the company’s financial position and support its continued listing on the Euronext Oslo Børs, potentially enhancing its market presence and operational capabilities.
The most recent analyst rating on (BRRGF) stock is a Buy with a NOK38.00 price target. To see the full list of analyst forecasts on BerGenBio ASA stock, see the BRRGF Stock Forecast page.
More about BerGenBio ASA
BerGenBio ASA operates in the biotechnology sector, focusing on developing innovative drugs for the treatment of cancer. The company is known for its research and development in targeted therapies, aiming to improve patient outcomes in oncology.
Average Trading Volume: 339,364
Current Market Cap: NOK45.42M
Learn more about BRRGF stock on TipRanks’ Stock Analysis page.